Mineralys Therapeutics, Inc. MLYS
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldos…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees76
TickerMLYS
Statistics
Market Cap$2.07B
Revenue (TTM)—
Net Income-$154.7M
Net Margin—
EPS$-2.29
P/E-10.31
P/S—
P/B3.00
EV/EBITDA-7.67
ROE-31.0%
Dividend Yield—
Price$25.15
Data: Twelve Data · Revenue = mcap / P/S